Imc Chicago, LLC Cassava Sciences Inc Transaction History

Imc Chicago, LLC

$3.02 Billion
Q3 2024

A detailed history of Imc Chicago, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Imc Chicago, LLC holds 39,792 shares of SAVA stock, worth $1.05 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

39,792

Holding current value

$1.05 Million

% of portfolio

0.04%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 25, 2024	BUY	$9.57 - $35.08 $380,809 - $1.4 Million	39,792 New	39,792 $1.17 Million
Q1 2024 Apr 12, 2024	SELL	$18.44 - $26.41 $21,703 - $31,084	-1,177 Reduced 6.66%	16,484 $334,000
Q4 2023 Feb 09, 2024	BUY	$12.64 - $30.11 $223,235 - $531,772	17,661 New	17,661 $397,000
Q1 2023 Apr 24, 2023	SELL	$23.46 - $36.44 $1.46 Million - $2.26 Million	-62,149 Closed	0 $0
Q4 2022 Feb 09, 2023	BUY	$27.82 - $44.16 $1.73 Million - $2.74 Million	62,149 New	62,149 $1.84 Million
Q2 2022 Aug 05, 2022	SELL	$17.22 - $38.47 $22,954 - $51,280	-1,333 Reduced 11.63%	10,132 $285,000
Q2 2021 Aug 06, 2021	BUY	$32.15 - $89.72 $368,599 - $1.03 Million	11,465 New	11,465 $980,000

Others Institutions Holding SAVA

# of Institutions

207

Shares Held

14M

Call Options Held

2.98M

Put Options Held

6.57M

Black Rock Inc. New York, NY

3.22M
Shares

$85.3 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.52M
Shares

$66.8 Million
0.0% of portfolio
State Street Corp Boston, MA

1.16M
Shares

$30.8 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.01M
Shares

$26.7 Million
0.0% of portfolio
Gallacher Capital Management LLC Lone Tree, CO

580K
Shares

$15.4 Million
7.83% of portfolio

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.06B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Imc Chicago, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Imc Chicago, LLC with notifications on news.

Account